ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event

3d ago

ASLN

PremiumPress Releases

ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics

8d ago

ASLN

PremiumPress Releases

ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab

10d ago

ASLN

PremiumCompany Announcements

Aslan Pharmaceuticals’ Eblasakimab Shows Promise

18d ago

ASLN

PremiumPress Releases

ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients

18d ago

ASLN

More ASLN News >

ASLN News on the Web

2024-05-09

ASLN Stock Earnings: ASLAN Pharma Beats EPS for Q1 2024

InvestorPlace

Neutral

2024-05-09

ASLAN Pharmaceuticals Excels in Eblasakimab Trials

TipRanks News

Neutral

2024-05-09

ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Yahoo Finance

Neutral

2024-05-07

ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event

Yahoo Finance

Neutral

2024-04-30

ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab

Yahoo Finance

Neutral

2024-04-24

ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference

Yahoo Finance

Neutral

2024-04-22

Aslan Pharmaceuticals’ Eblasakimab Shows Promise

TipRanks News

Neutral

2024-04-22

ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients

Yahoo Finance

Neutral

News Score - Last 7 Days

Neutral

ASLN

Sector Average

Media Buzz

This Week4 articles

Weekly Average2.25 articles

News Sentiment

This Week50%

Sector Average60%

See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is ASLN’s Media Buzz Sentiment?

4 articles about ASLN were published this week. In an average week, 2.25 articles are published.

What is ASLN’s weekly average amount of articles?

In an average week, 2.25 articles about ASLN are published.

What is ASLN’s News Sentiment?

50% of articles about ASLN were positive this week, compared to its sector average of 60%.

Healthcare Stocks that are Trending in the News

CLDXCelldex

GOSSGossamer Bio

RCKTRocket Pharmaceuticals

HAEHaemonetics

IMCRImmunocore Holdings

Showing the stocks with the most bullish news sentiment over the past week

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing